Current Applications for Overcoming Resistance to Targeted Therapies

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Szewczuk, Myron R. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Qorri, Bessi (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Sambi, Manpreet (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
• Έκδοση: 1st ed. 2019.
• Σειρά: Resistance to Targeted Anti-Cancer Therapeutics, 20
• Θέματα: Cancer research.; Molecular biology.; Cancer Research.; Molecular Medicine.
• Φυσική περιγραφή: XVIII, 320 p. 31 illus., 29 illus. in color. online resource.
• ISBN: 9783030214777
• ISSN: 2196-5501 ;
• DOI: 10.1007/978-3-030-21477-7

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.